Customization of therapy for gastroesophageal adenocarcinoma patients
Gastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can...
Guardado en:
Autores principales: | Dilsa Mizrak Kaya, Kazuto Harada, Fatemeh G. Amlashi, Maria Vasilakopoulou, Jaffer A. Ajani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/67582d5f1347400690565480df29ae11 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Perceptions of patient-centered care among veterans with gastroesophageal reflux disease on proton pump inhibitor therapy
por: Salva Balbale, et al.
Publicado: (2018) -
Colonic interposition for recurrent Gastroesophageal junction adenocarcinoma of stomach: a case report
por: Sujan Regmee, et al.
Publicado: (2020) -
Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction
por: Yuan Lin, et al.
Publicado: (2020) -
Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair
por: Dewalt RI, et al.
Publicado: (2014) -
Adenocarcinoma of the Gastroesophageal Junction with Synchronous Renal Cell Carcinoma: A Case Report and Literature Review
por: Yankov G., et al.
Publicado: (2020)